Clinical Trial Update: Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of Irinotecan hydrochloride liposome injection (LY01610) for Small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Irinotecan hydrochloride liposome injection (LY01610) (irinotecan hydrochloride liposome injection)

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED